Boltz raises $110 million to build AI models for drug design
London-based AI drug discovery startup Boltz has raised a $110 million Series A, less than a year after coming out of stealth with a $28 million seed round. Bessemer Venture Partners led the round, joined by existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New backers include Greycroft, F-Prime Capital, Hummingbird and Benchling, alongside Nvidia, which announced an investment earlier this year.
Boltz builds models that help pharmaceutical and biotech researchers design potential drugs and choose which candidates to test in the lab. Its models predict how a protein and a drug candidate look when bound together, estimate how strongly they bind, and propose new molecules designed for a target. Its co-founders released open-source models at MIT that matched the performance of closed models such as DeepMind's AlphaFold3.
The company, spun out of MIT and now employing 40 AI researchers in London's King's Cross, has announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb. It earns money from partnerships and from access to its platform and custom models. In its own announcement, Boltz says it has signed partnerships with six of the world's 20 largest pharma companies and that molecular token usage among paying customers has grown 50-fold since June, when it released its first proprietary models, BoltzMol-1 and BoltzProt-1.
"Our upcoming models are already showing substantial improvements in the quality of the molecules they generate," the company said, adding that its goal requires substantial investment in compute and data, according to Tech.eu.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 19 IntelliProve raises €2.7 million to measure vital signs through any camera Nov 19 MegaRobo raises nearly $200 million to let AI run real lab experiments Nov 18 AlphaFold screen maps nearly 2,900 likely interactions among human mitochondrial proteins Nov 18 Hone Health raises $228 million to expand AI-enabled longevity care Nov 18 Tesorai raises $5.3 million to make raw lab data searchable with AIMore from Funding
Nov 19 Deutsche Telekom invests €100 million in Mistral AI Nov 19 LATO raises $4.7 million for AI agents that interview customers for investors Nov 19 Noah raises €800,000 for an AI interviewer that maps where companies can use AI Nov 19 Wilgot raises $3 million to rewrite product pages for AI shopping agents Nov 19 IntelliProve raises €2.7 million to measure vital signs through any cameraAI in Europe
Daily AI news from Europe, chosen by Rene van Pelt: European companies, the EU and the UK, chips and data centres, deals and regulation, in a few minutes.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Isomorphic Labs raises $5 billion Series C for AI drug design
London's Model ML raises $250M at a $1.5B valuation for AI agents for bankers and consultants
Biomatter Raises $18 Million for AI Enzyme Design
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Daily AI Brief: the AI news that matters, in your inbox.